4-aminobenzoic acid has been researched along with Angioedemas, Hereditary in 1 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
Angioedemas, Hereditary: Inherited disorders that are characterized by subcutaneous and submucosal EDEMA in the upper RESPIRATORY TRACT and GASTROINTESTINAL TRACT.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martinez-Zapata, MJ | 1 |
| Vernooij, RW | 1 |
| Simancas-Racines, D | 1 |
| Uriona Tuma, SM | 1 |
| Stein, AT | 1 |
| Moreno Carriles, RMM | 1 |
| Vargas, E | 1 |
| Bonfill Cosp, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patie[NCT02191163] | Phase 2 | 71 participants (Actual) | Interventional | 2002-04-30 | Completed | ||
| Randomized, Double-blind Multicenter Clinical Trial Comparing the Efficacy of Calcium Dobesilate With Placebo in the Treatment of Ulcer Secondaries to Chronic Venous Disease[NCT00979836] | Phase 3 | 230 participants (Anticipated) | Interventional | 2008-04-30 | Suspended (stopped due to The financial support was withdrawn.) | ||
| Evaluation of Efficacy and Safety of the Fixed-dose Combination of Coumarin and Troxerutin (Venalot®) Versus Placebo in the Symptomatic Treatment of Chronic Venous Insufficiency - VENACT[NCT01848210] | Phase 4 | 829 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study[NCT02191280] | Phase 2 | 260 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency[NCT02191254] | Phase 3 | 245 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Assessment of the Efficacy and Safety of Diosmin 600mg on Painful Symptomatology in Patients With Chronic Venous Disease of Lower Limbs: a Multicentric, Randomised, Double-blind, Placebo-controlled Trial in Parallel Groups[NCT01532882] | Phase 3 | 378 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Study of Antiinflammatory Effects of Detralex (Daflon) in Patients With Chronic Venous Disease[NCT01654016] | Phase 4 | 84 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Local Complaint Severity will be assessed using the Severity Score of Local Complaints that comprises 8 items: 1=tired legs, 2=heavy legs, 3= feeling of tension, 4=feeling of swelling, 5=aching legs, 6=tingling, 7=itching, 8=burning of soles of the feet.~Each item is classified with a Likert-type scale of 5 levels, where 0=absent, 1=low, 2=medium, 3=high, 4=very high.~A total score is calculated from the sum of the scores of all the 8 items and ranges from 0 (complaints absent) to 32 (very high severity)." (NCT01848210)
Timeframe: Baseline and Week 16
| Intervention | score on a scale (Mean) |
|---|---|
| Coumarin + Troxerutin | 10.83 |
| Placebo | 10.45 |
Change in the partial volume of legs will be measured using a water plethysmometer. The volume of water (at 34 ± 0.2 °C) displaced after limb immersion is collected in an empty plastic Beaker which has been previously weighed (scale tare). The equilibrium/stability will be estimated using the absolute difference between measures of volume obtained at the Week 16 visit and Baseline to determine the reduction in edema. (NCT01848210)
Timeframe: Baseline and Week 16
| Intervention | milliliters (mL) (Mean) |
|---|---|
| Coumarin + Troxerutin | 1.13 |
| Placebo | 5.78 |
Adverse events are any unwanted medical occurrences in an individual taking part in a clinical study who is receiving a pharmaceutical product. The adverse event does not have necessarily a causal relationship with the treatment. In this definition, any adverse or unwanted signals and symptoms, or findings that appear from the start or that deteriorate during the clinical study are also included, i.e. any intercurrent diseases (recently diagnosed concomitant diseases or symptoms), accidents and clinically relevant changes in clinical laboratory values. (NCT01848210)
Timeframe: Baseline to Week 16
| Intervention | participants (Number) |
|---|---|
| Coumarin + Troxerutin | 131 |
| Placebo | 120 |
The investigator recorded their impression of the overall clinical picture at the end of the treatment period (Week 16), taking into account the clinical picture compared with the Baseline visit. Data is reported for the percentage of participants in each of the following assessment categories: worsening, unchanged, discreet improvement or accentuated improvement. (NCT01848210)
Timeframe: Baseline and Week 16
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Worsening | Unchanged | Discreet improvement | Accentuated improvement | |
| Coumarin + Troxerutin | 0.6 | 11.2 | 25.3 | 62.9 |
| Placebo | 0.8 | 14.3 | 24.4 | 60.4 |
1 review available for 4-aminobenzoic acid and Angioedemas, Hereditary
| Article | Year |
|---|---|
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |
Phlebotonics for venous insufficiency.
Topics: 4-Aminobenzoic Acid; Angioedemas, Hereditary; Calcium Dobesilate; Centella; Chronic Disease; Diosmin | 2020 |